Galectin-3 (Gal-3) is a multifunctional β-galactoside–binding lectin implicated in fibrosis, cancer, cardiovascular and kidney diseases, inflammation, and neurodegenerative disorders. It regulates cell adhesion, apoptosis, immune responses, and extracellular matrix remodeling, with elevated expression associated with tumor progression, metastasis, heart failure, chronic kidney disease, and Alzheimer’s disease. Catalina’s rigorously validated Galectin-3 antibodies provide high specificity and reproducibility for accurate detection and quantification of Gal-3 in diverse biological contexts. These reagents support advanced research in fibrosis signaling, cancer biology, immune modulation, biomarker validation, neurodegeneration, and therapeutic antibody development.